[1] World Health Organization. HIV/AIDS[EB]. (2020-11-30)[2021-05-18]. https://www.who.int/news-room/fact-sheets/detail/hiv-aids.
[2] Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, Fleming TR; HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission[J]. N Engl J Med, 2016, 375:830-839.
[3] Rojas-Celis V, Valiente-Echeverría F, Soto-Rifo R, Toro-Ascuy D. New challenges of HIV-1 infection:how HIV -1 attacks and resides in the central nervous system[J]. Cells, 2019, 8:1245.
[4] Hogan C, Wilkins E. Neurological complications in HIV[J]. Clin Med (Lond), 2011, 11:571-575.
[5] Paruk HF, Bhigjee AI. Review of the neurological aspects of HIV infection[J]. J Neurol Sci, 2021.[Epub ahead of print]
[6] Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA; UK Collaborative HIV Cohort (CHIC) study. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease[J]. Neurology, 2011, 76:693-700.
[7] Bowen LN, Smith B, Reich D, Quezado M, Nath A. HIV-associated opportunistic CNS infections:pathophysiology, diagnosis and treatment[J]. Nat Rev Neurol, 2016, 12:662-674.
[8] Manzardo C, Guardo AC, Letang E, Plana M, Gatell JM, Miro JM. Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era:a comprehensive review[J]. Expert Rev Anti Infect Ther, 2015, 13:751-767.
[9] Navis A, Siddiqi O, Chishimba L, Zimba S, Morgello S, Birbeck GL. Immune reconstitution inflammatory syndrome in the central nervous system:limitations for diagnosis in resource limited settings[J]. J Neurol Sci, 2020, 416:117042.
[10] Wu G, Guo X, Wang Y, Hu Z. Clinical and radiographic features of cryptococcal neoformans meningitis-associated immune reconstitution inflammatory syndrome[J]. Sci Rep, 2020, 10:9948.
[11] Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy[J]. J Clin Virol, 2001, 22:279-287.
[12] French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy[J]. AIDS, 2004, 18:1615-1627.
[13] Hammoud DA, Boulougoura A, Papadakis GZ, Wang J, Dodd LE, Rupert A, Higgins J, Roby G, Metzger D, Laidlaw E, Mican JM, Pau A, Lage S, Wong CS, Lisco A, Manion M, Sheikh V, Millo C, Sereti I. Increased metabolic activity on 18F-Fluorodeoxyglucose positron emission tomography-computed tomography in human immunodeficiency virus-associated immune reconstitution inflammatory syndrome[J]. Clin Infect Dis, 2019, 68:229-238.
[14] Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy[J]. Pharmacogenomics, 2009, 10:623-637.
[15] Decloedt EH, Maartens G. Neuronal toxicity of efavirenz:a systematic review[J]. Expert Opin Drug Saf, 2013, 12:841-846.
[16] Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC, Simpson DM, Ake C, Collier AC, Gelman BB, McCutchan JA, Morgello S, Grant I; CHARTER Group. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy[J]. Ann Neurol, 2008, 64:566-572.
[17] Peñafiel J, Lazzari E, Padilla M, Rojas J, Gonzalez-Cordon A, Blanco JL, Blanch J, Marcos MA, Lonca M, Martinez-Rebollar M, Laguno M, Tricas A, Rodriguez A, Mallolas J, Gatell JM, Martinez E. Tolerability of integrase inhibitors in a real-life setting[J]. J Antimicrob Chemother, 2017, 72:1752-1759.
[18] Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated research nosology for HIV-associated neurocognitive disorders[J]. Neurology, 2007, 69:1789-1799.
[19] Nightingale S, Dreyer AJ, Saylor D, Gisslén M, Winston A, Joska JA. Moving on from HAND:why we need new criteria for cognitive impairment in people with HIV and a proposed way forward[J]. Clin Infect Dis, 2021.[Epub ahead of print]
[20] Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin A, Ragin A, Levine A, Miller E. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study[J]. Neurology, 2016, 86:334-340.
[21] Eggers C, Arendt G, Hahn K, Husstedt IW, Maschke M, Neuen-Jacob E, Obermann M, Rosenkranz T, Schielke E, Straube E; German Association of Neuro-AIDS und Neuro-Infectiology (DGNANI). HIV-1-associated neurocognitive disorder:epidemiology, pathogenesis, diagnosis, and treatment[J]. J Neurol, 2017, 264:1715-1727.
[22] Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, Gisslén M, Angoff N, Price RW, Cinque P, Spudich S. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load[J]. AIDS, 2012, 26:1765-1774.
[23] Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection[J]. Neurology, 2011, 76:444-450.
[24] Benjamin LA, Corbett EL, Connor MD, Mzinganjira H, Kampondeni S, Choko A, Hopkins M, Emsley HC, Bryer A, Faragher B, Heyderman RS, Allain TJ, Solomon T. HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults:a case-control study[J]. Neurology, 2016, 86:324-333.
[25] Moulignie A, Savatovsky J, Assoumou L, Lescure FX, Lamirel C, Godin O, Valin N, Tubiana R, Canestri A, Roux P, Sadik JC, Salomon L, Abrivard M, Katlama C, Yazdanpanah Y, Pialoux G, Girard PM, Costagliola D; Microvascular Brain Retina and Kidney (MicroBREAK) Study Group. Silent cerebral small-vessel disease is twice as prevalent in middle-aged individuals with well-controlled, combination antiretroviral therapy-treated Human Immunodeficiency Virus (HIV) than in HIV-uninfected individuals[J]. Clin Infect Dis, 2018, 66:1762-1769.
[26] Nguyen I, Kim AS, Chow FC. Prevention of stroke in people living with HIV[J]. Prog Cardiovasc Dis, 2020, 63:160-169.
[27] Mullin S, Temu A, Kalluvya S, Grant A, Manji H. High prevalence of distal sensory polyneuropathy in antiretroviral-treated and untreated people with HIV in Tanzania[J]. Trop Med Int Health, 2011, 16:1291-1296.
[28] Chen H, Clifford DB, Deng L, Wu K, Lee AJ, Bosch RJ, Riddler SA, Ellis RJ, Evans SR. Peripheral neuropathy in ART-experienced patients:prevalence and risk factors[J]. J Neurovirol, 2013, 19:557-564.
[29] Julian T, Rekatsina M, Shafique F, Zis P. Human immunodeficiency virus-related peripheral neuropathy:a systematic review and meta-analysis[J]. Eur J Neurol, 2021, 28:1420-1431.
[30] Bouhassira D, Attal N, Willer JC, Brasseur L. Painful and painless peripheral sensory neuropathies due to HIV infection:a comparison using quantitative sensory evaluation[J]. Pain, 1999, 80:265-272.
[31] Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection:clinical, electrophysiologic, and laboratory findings[J]. Arch Neurol, 1999, 56:84-89.
[32] Mallet ML, Hadjivassiliou M, Sarrigiannis PG, Zis P. The role of oxidative stress in peripheral neuropathy[J]. J Mol Neurosci, 2020, 70:1009-1017. Hahn K, Arendt G, Braun JS, von Giesen HJ, Husstedt IW, Maschke M, Straube ME, Schielke E; German Neuro-AIDS Working Group. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies[J]. J Neurol, 2004, 251:1260-1266.